Strumento inattivo

Altre lingue InspireMD Inc Nyse

Azioni

US45779A5074

Prezzo di chiusura Nyse Altri mercati azionari
- ^USD	-

14/05	Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
13/05	InspireMD, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million	01/07
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial of CGuard at LINC 2024	29/05
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024	28/05
Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	14/05
InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
InspireMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07/05
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26/03
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	06/03
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06/03
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28/02
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12/02
InspireMD Gets CE Mark Recertification From the European Union	31/01
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31/01
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03/01
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	03/01
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	20/12
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue InspireMD Inc Nyse

Azioni

US45779A5074

Altre lingue

Filtri